Germany’s health minister Jen Spahn is seeking to resolve a long-running dispute with the European Commission over… https://t.co/7A8HWXxOJs
When Healthcare Budget Cuts Are Not the Answer: Lessons from Taiwan
While attending the ISPOR 5th Asia-Pacific Conference at the Taipei International Convention Center in early September, I was impressed by Taiwan's calm and tranquility. The people there are enjoying universal health insurance coverage, with a single payer ensuring low-cost but quality healthcare for all the citizens. Everyone seems to be happy: the healthcare consumers "can afford to be sick," while the pharmaceutical companies enjoy steady growth. Looking forward, I expect the healthcare market to keep growing, driven by the momentum unleashed by the universal coverage.
At the conference, I also joined heated discussions over the challenges faced by many Eurozone countries-quite a contrast to Taiwan. The Eurozone governments' austerity policy has led to budget cuts on public healthcare expenditure with adverse consequences.
Like Nobel Prize winner Professor Krugman, I question the wisdom of budget cutting at the height of recession-whether it was during the Asian financial crisis of the late 1990s or the global financial crisis of 2008-it delays economic recovery and hurts the healthcare market.
To be specific, on the demand side, the governments' cost-cutting policy has led to reduced healthcare expenditure and payments by the governments, while the private sector has not picked up the slack. Consumers burdened with higher co-payments have reduced medical treatment. As a result, the demand for drugs has fallen, thereby driving down pharmaceutical sales.
On the supply side, pharmaceutical companies-already facing post-patent-expiry price competition from generics and biosimilars-have responded to Governments'reduced reimbursement and drug prices with reduced investment or even withdrawals, thus reducing drug supplies.
The interweaving of demand and supply factors has led to a net reduction in prices, drug sales and patients' access to drugs. In the end, no one is happy: the pharmaceutical companies end up with reduced revenue, while the consumers end up with reduced access to drugs and healthcare. Against such a backdrop, I expect the Eurozone to have negative growth in health spend in 2012.
As I was about to leave the conference, someone asked me: "When will the Eurozone start to have strong growth in drug sales and health spend again?" My answer: "when the economy is fully recovered and that will be many years away."
- Challenges with risk sharing in Eastern Europe raised at ISPOR Europe meeting
- Germany’s fixed pricing for medicines faces European reckoning
- Dynamic reform in International Reference Pricing
- Ten-year Medicare budget impact of increased coverage for anti-obesity intervention
- South Korean pharma dreams struggle
- The economic burden of elevated blood glucose levels in 2017 in the United States
- Taking the pulse of international reference pricing
- Irish green credentials fail on pharmaceutical waste exports
We are at ISPOR! To find out more about our nuanced insights on IRP policy evolution, please check out the latest… https://t.co/XdatTuUwts
Slovakia approved legislation to curtail alleged manufacturer attempts to circumvent IRP-related price reductions b… https://t.co/qAANBeyyyN